0001209191-17-005608.txt : 20170125 0001209191-17-005608.hdr.sgml : 20170125 20170125191910 ACCESSION NUMBER: 0001209191-17-005608 CONFORMED SUBMISSION TYPE: 3 PUBLIC DOCUMENT COUNT: 2 CONFORMED PERIOD OF REPORT: 20170125 FILED AS OF DATE: 20170125 DATE AS OF CHANGE: 20170125 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Lydon Nicholas CENTRAL INDEX KEY: 0001639935 FILING VALUES: FORM TYPE: 3 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 17547682 MAIL ADDRESS: STREET 1: BLUEPRINT MEDICINES CORP. STREET 2: 215 FIRST STREET, SUITE 340/350 CITY: CAMBRIDGE STATE: MA ZIP: 02142 3 1 doc3.xml FORM 3 SUBMISSION X0206 3 2017-01-25 0 0001370053 ANAPTYSBIO INC ANAB 0001639935 Lydon Nicholas C/O ANAPTYSBIO, INC. 10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121 1 0 0 0 Common Stock 67332 D Series B Preferred Stock 0.00 Common Stock 80877 D Series C Preferred Stock 0.00 Common Stock 55403 D Series D Preferred Stock 0.00 Common Stock 67345 D Director Stock Option (right to buy) 1.12 2021-12-08 Common Stock 6828 D Director Stock Option (right to buy) 0.70 2024-07-10 Common Stock 24184 D Warrant to Purchase Series C Preferred Stock (right to buy) 4.55 2018-11-04 Series C Preferred Stock 16483 D Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date. The stock option is fully vested and immediately exercisable. The stock option vested and became exercisable as to 25% of the shares subject to the option on January 1, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing service of the Reporting Person on each vesting date. This warrant is exercisable at any time. /s/ Nicholas B. Lydon by Dominic Piscitelli, Attorney-in-Fact 2017-01-25 EX-24.3_696755 2 poa.txt POA DOCUMENT POWER OF ATTORNEY KNOW ALL MEN BY THESE PRESENTS, that the undersigned hereby constitutes and appoints Hamza Suria, Dominic Piscitelli, Ryan McRobert, Nanette Agustines and Winston Macaraeg, and each of them, as his or her true and lawful attorney-in-fact to: (1) execute for and on behalf of the undersigned, in the undersigned's capacity as a representative of AnaptysBio, Inc. (the "Company"), any and all Form ID, or Form 3, 4 or 5 reports and any amendments thereto required to be filed by the undersigned in accordance with Section 16(a) of the Securities Exchange Act of 1934 (the "Exchange Act") and the rules thereunder with respect to transactions in the Company's securities; (2) do and perform any and all acts for and on behalf of the undersigned which may be necessary or desirable to complete and execute any such Form ID, or Form 3, 4 or 5 report and any amendments thereto and timely file such report with the U.S. Securities and Exchange Commission and any stock exchange or similar authority; and (3) take any other action of any type whatsoever in connection with the foregoing which, in the opinion of such attorney in-fact, may be of benefit to, in the best interest of, or legally required by, the undersigned, it being understood that the documents executed by such attorney in-fact on behalf of the undersigned, pursuant to this Power of Attorney, shall be in such form and shall contain such terms and conditions as such attorney in-fact may approve in his or her discretion. The undersigned hereby grants to each such attorney-in-fact full power and authority to do and perform each and every act and thing whatsoever requisite, necessary, and proper to be done in the exercise of any of the rights and powers herein granted, as fully to all intents and purposes as the undersigned might or could do if personally present, with full power of substitution or revocation, hereby ratifying and confirming all that such attorney-in-fact, or his or her substitute or substitutes, shall lawfully do or cause to be done by virtue of this Power of Attorney and the rights and powers herein granted. The undersigned acknowledges that no such attorney in-fact, in serving in such capacity at the request of the undersigned, is hereby assuming, nor is the Company hereby assuming, any of the undersigned's responsibilities to comply with Section 16 of the Exchange Act. This Power of Attorney shall remain in full force and effect until the undersigned is no longer required to file Form 3, 4 or 5 reports with respect to the undersigned's holdings of and transactions in securities issued by the Company, unless earlier revoked by the undersigned in a signed writing delivered to the foregoing attorneys in-fact. IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney to be executed as of this 20th day of January, 2017. /s/ Nicholas B. Lydon Nicholas B. Lydon